Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery

Prospective, Open-Label, Multi-Center, Phase III CLinical Study to Investigate the Efficacy and Safety of Human Factor VWF/FVIII Concentrate (Wilate) in Subjects With Inherited Von Willebrand Disease Who Undergo Surgical Procedures

Proportion of surgeries in which the primary endpoint (overall assessment) is classified as success.

Inclusion Criteria:

• Diagnosed with congenital VWD (von Willebrand Disease)
• Require therapy with a VWF (von Willebrand Factor) product to treat any major surgical procedure

Exclusion Criteria:

• Known coagulation disorder other than VWD
• Known history of, or suspected VWF or FVIII inhibitors
• Subjects with hepatic liver disease
• Known or suspected hypersensitivity or previous evidence of severe side effects to wilate or other VWF/FVIII concentrates
• Pregnant women in the first 20 weeks of gestation